Dr. Sonpavde on Trials of Immunotherapy in Bladder Cancer

Guru Sonpavde, MD
Published: Thursday, May 17, 2018



Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses current trials of immunotherapy in bladder cancer.

The second-line therapy of bladder cancer has been revolutionized by the approvals of multiple PD-1/PD-L1 inhibitors. There are many trials currently ongoing trying to move checkpoint inhibitors to the first-line setting, says Sonpavde. In the cisplatin-ineligble space, pembrolizumab (Keytruda) and atezolizumab (Tecentriq) are currently approved by the FDA.

Durvalumab (Imfinzi), nivolumab (Opdivo), and the combination of nivolumab and ipilimumab (Yervoy) are all being investigated in phase III trials for the first-line setting of advanced urothelial carcinoma.

There are also ongoing clinical trials evaluating the combination of checkpoint inhibitors with platinum-based chemotherapy in the first-line setting. These trials include patients who are eligible for cisplatin and those who are not, Sonpavde says. Another strategy under investigation is combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors.


Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses current trials of immunotherapy in bladder cancer.

The second-line therapy of bladder cancer has been revolutionized by the approvals of multiple PD-1/PD-L1 inhibitors. There are many trials currently ongoing trying to move checkpoint inhibitors to the first-line setting, says Sonpavde. In the cisplatin-ineligble space, pembrolizumab (Keytruda) and atezolizumab (Tecentriq) are currently approved by the FDA.

Durvalumab (Imfinzi), nivolumab (Opdivo), and the combination of nivolumab and ipilimumab (Yervoy) are all being investigated in phase III trials for the first-line setting of advanced urothelial carcinoma.

There are also ongoing clinical trials evaluating the combination of checkpoint inhibitors with platinum-based chemotherapy in the first-line setting. These trials include patients who are eligible for cisplatin and those who are not, Sonpavde says. Another strategy under investigation is combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x